Manufacturers announce positive interim results from long-term study of efficacy and safety of ozanimod in relapsing forms of multiple sclerosis

In the phase 3 open-label extension trial DAYBREAK (n=2494), 79% and 75% of participants, respectively, were relapse-free at months 24 and 36, with 3 and 6 month confirmed disability progression observed in 10.8% and 8.6%, respectively, and 9.5% had treatment-emergent ADRs.


Biospace Inc.